Lung Cancer: Risk Factors, Newly Approved Therapies and the Role of the Pharmacist in Lung Cancer Therapy

MENA

$0

free

SCFHS

1 hr

Oncology

1.0 Credits

This course is expired! Browse All Courses
LEARN MORE

Course Description

Recent literature demonstrates that lung cancer represents around 4% of cancers diagnosed cancers in the Kingdom of Saudi Arabia (KSA). It is the 4th most common cancer in men and the 17th most common cancer in women.

The objective of this online program is to help educate and support pharmacists in KSA in understanding the current landscape of lung cancer: genetic mutations, risk factors, and treatment approaches. The module reviews Saudi lung cancer management guidelines, discusses adverse events that may occur with treatment, and Saudi guidelines for the management of these adverse events.

This program is supported by Novartis.

Course Details

Expiry Date: 2024-07-27

Professions: Pharmacy, Specialist

Faculty

Abdul-Rahman Jazieh, MD, MPH

Nora Alkhudair, reviewer

Accreditation

This program is accredited by the Saudi Commission for Health Specialties for 1.0 CPD Hour(s). Activity Accreditation Number: ACA‐20230002494. 

Credits are reported to the Saudi Commission for Health Specialties on a monthly basis. Please ensure that your Saudi Commission ID is accurate in your profile and allow sufficient time for credits to appear in your Mustamir account.

This program is approved for the following professions: Medical Oncology, Thoracic and Cardiac Surgery, Radiation Oncology, Pulmonology, Thoracic Surgery, Pediatric Oncology, Pharmaceutical Sciences, Clinical Pharmacy, Pharmaceutical administration and outcomes, Pharmacy.

Learning Objective(s)

Upon completion of this continuing education program, participants will be better able to:

  • Describe
    relevant genetic mutations seen in lung cancer
  • Outline
    risk factors and preventive strategies for lung cancer
  • Discuss
    Saudi guidelines for the treatment of lung cancer
  • Recognize
    common adverse events associated with the treatment of lung cancer, especially
    immune-related adverse events, and implement strategies to mitigate them.

This course is expired! Browse All Courses